-Bloomberg
Related Posts
Biden Administration Forms Review Board To Probe Cybersecurity Failures
-Wall Street Journal
-Wall Street Journal
Needham Maintains Buy on Azenta, Lowers Price Target to $115
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $155 to $115.
Needham Maintains Buy on OncoCyte, Lowers Price Target to $1.4
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $2.1 to $1.4.